Ghost Tree Capital’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Ghost Tree Capital’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-25,000	Closed	-$2.67M	–	96
2015 Q1	$2.67M	Buy	+25,000	New	+$2.38M	0.96%	46

Other funds holding PTX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ghost Tree Capital's PTX Position: Q2 2015 in Review

Ghost Tree Capital sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2015, closing a stake of 25,000 shares — an estimated $2.67M sold.

Ghost Tree Capital first reported a position in PTX in Q1 2015 and held it in 1 quarter. The position peaked at $2.67M in Q1 2015. 114 funds tracked by Wall St. Rank hold PTX as of Q2 2015.

Ghost Tree Capital reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2015 after selling out during the quarter.
Ghost Tree Capital sold 25,000 Pernix Therapeutics Holdings, Inc. shares in Q2 2015, an estimated $2.67M.
Ghost Tree Capital first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2015 and held it in 1 quarter.
Ghost Tree Capital's Pernix Therapeutics Holdings, Inc. position peaked at $2.67M in Q1 2015.
114 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2015.

Based on Ghost Tree Capital's 13F filing for Q2 2015, filed 14 Aug 2015.